Table 2.

Liposomal Formulations of Anticancer Drugs in Clinical Trials.

Product name	Encapsulated drugs	Type of liposomes	Indications	Status	Ref
Alocrest	Vinorelbine	Optisomes	NSCLC and breast cancers, non-Hodgkin lymphoma, Hodgkin disease	Phase I	60
ATI-1123	Docetaxel	Protein-stabilized liposomes	NSCLC, gastric, pancreatic cancer, and soft tissue sarcoma	Phase I	61
MCC-465	Doxorubicin	Antibody-conjugated PEGylated liposomes	Stomach cancer	Phase I	62
NanoVNB	Vinorelbine	PEGylated liposomes	Advanced solid tumors	Phase I	63
IHL-305	Irinotecan	PEGylated liposome	Advanced solid tumors	Phase I	64
EndoTAG-1	Paclitaxel	Cationic liposomes	Solid tumors	Phase II	65,66
LEP-ETU	Paclitaxel	Anionic liposomes	Metastatic breast cancer	Phase II	67
MBP-426	Oxaliplatin	Tf-conjugated liposomes	Gastric, gastroesophageal, esophageal adenocarcinomas	Phase II	68
CPX-351	Cytarabine and daunorubicin (5:1)	Bilamellar liposomes	Acute myeloid leukemia	Phase III	69,70
Lipoplatin	Cisplatin	PEGylated liposomes	NSCLC, gastric, pancreatic, breast, head and neck cancers	Phase III	71,72
MM-398 (PEP02)	Irinotecan	PEGylated liposomes	Metastatic pancreatic cancer	Phase III	73
ThermoDox	Doxorubicin	Lysolipid temperature sensitive liposomes	Hepatocellular carcinoma and breast cancer	Phase III	74